Super Trial
A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess the Immunological Response and Safety Profile of a Single Dose BPZE1 With and Without Co-Administration of Tetanus, Diphtheria, and Acellular Pertussis (Boostrix™)
This is an international study enrolling 600 children/teenagers aged 6 to 16 years old and is being funded by a company called ILiAD Biotechnologies.